Overcoming resistance to EGFR-TKI in NSCLC by simultaneously inhibition of anti-apoptotic proteins

被引：0
|
作者：
Weller, Sandra
Beigl, Tobias
Essmann, Frank
Harsch, Annika
Kopp, Hans-Georg
Ekstrom, Tom
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6484
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6484
引用
收藏
页数：2
相关论文
共 50 条
  • [21] In vitro study on blocking mTOR signaling pathway in EGFR-TKI resistance NSCLC
    Xiang, Xu-Dong
    Yu, Jing
    Li, Gao-Feng
    Xie, Lin
    Li, Heng
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2014, 7 (05) : 394 - 397
  • [22] EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
    Zhu, Xuan
    Chen, Lijie
    Liu, Ling
    Niu, Xing
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [23] Overcoming Resistance to Apoptosis in Multiple Myeloma By Simultaneous Inhibition of Bcl2 and IAP Families of Anti-Apoptotic Proteins
    Gomez, Marcus
    Ramakrishnan, Vijay G.
    Prasad, Vivek
    Kimlinger, Teresa K.
    Painuly, Utkarsh
    Bi, Lintao
    Rajkumar, Vincent
    Kumar, Shaji
    BLOOD, 2014, 124 (21)
  • [24] Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
    Lee, Jeong Eun
    Park, Hee Sun
    Lee, Dahye
    Yoo, Geon
    Kim, Tackhoon
    Jeon, Haeyon
    Yeo, Min-Kyung
    Lee, Choong-Sik
    Moon, Jae Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    Park, Dong Il
    Park, Yeon Hee
    Lee, Jae Cheol
    Oh, In-Jae
    Lim, Dae Sik
    Chung, Chaeuk
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (01) : 154 - 160
  • [25] EGFR-TKI Treatment and Surgical Resection for Oligometastatic NSCLC?
    Klomp, Houke M.
    Kappers, Ingrid
    ONKOLOGIE, 2009, 32 (11): : 627 - 628
  • [26] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Ren, Shengxiang
    Li, Wei
    Li, Aiwu
    Chen, Xiaoxia
    Gao, Guanghui
    He, Yayi
    Li, Xuefei
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
  • [27] Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study
    Peng, P.
    Chen, Y.
    Han, G.
    Meng, R.
    Zhang, S.
    Liao, Z.
    Zhang, Y.
    Gong, J.
    Xiao, C.
    Liu, X.
    Zhang, P.
    Zhang, L.
    Xia, S.
    Chu, Q.
    Chen, Y.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S250 - S251
  • [28] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [29] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [30] The mutation profile of genes related to primary resistance to EGFR-TKI in early NSCLC.
    Ye, Jiangang
    Zhang, Qi
    Zhang, Xing
    Qin, Huijuan
    Tian, Minqi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345